Name: in vivo assay for detection of antigen-specific t-cell cytolytic function using a vaccination model
Uploaded: 2017-11-28T12:30:00
Description: Watch this Scientific Journal Video about In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model at JoVE.com

This work is supported by NIH research (A1R03AI120027 (RN) and 1R21AI20012 (RN)), Institutional Research Grant (RN), start-up grant (RN), and MD Anderson CIC seed grant (RN).

All methods described here have been approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Texas MD Anderson Cancer Center.
1. Preparation of Peptide for the Vaccine
<ol>
	<li>Dissolve the lyophilized peptide with phosphate-buffered saline (PBS) to the appropriate concentration and vortex for 30 s. 
	NOTE: For hgp10025-33, the final concentration is 1 mg/mL and for OVA257-264, the final ...

<ol>
	<li>Liu, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Visualization+and+quantification+of+T+cell-mediated+cytotoxicity+using+cell-permeable+fluorogenic+caspase+substrates.">Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates.</a> Nat Med. 8 (2), 185-189 (2002).</li><li>Wherry, E. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lineage+relationship+and+protective+immunity+of+memory+CD8+T+cell+subsets.">Lineage relationship and protective immunity of memory CD8 T cell subsets.</a> Nat Immunol. 4 (3), 225-234 (2003).</li><li>He, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+sensitive+flow+cytometry-based+cytotoxic+T-lymphocyte+assay+through+detection+of+cleaved+caspase+3+in+target+cells.">A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells.</a> J Immunol Methods. 304 (1-2), 43-59 (2005).</li><li>Barber, D. L., Wherry, E. J., Ahmed, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cutting+edge:+rapid+in+vivo+killing+by+memory+CD8+T+cells.">Cutting edge: rapid in vivo killing by memory CD8 T cells.</a> J Immunol. 171 (1), 27-31 (2003).</li><li>Quah, B. J., Wijesundara, D. K., Ranasinghe, C., Parish, C. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+use+of+fluorescent+target+arrays+for+assessment+of+T+cell+responses+in+vivo.">The use of fluorescent target arrays for assessment of T cell responses in vivo.</a> J Vis Exp. (88), e51627 (2014).</li><li>Johansson, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Natural+killer+cell+education+in+mice+with+single+or+multiple+major+histocompatibility+complex+class+I+molecules.">Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules.</a> J Exp Med. 201 (7), 1145-1155 (2005).</li><li>Hailemichael, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Persistent+antigen+at+vaccination+sites+induces+tumor-specific+CD8(+)+T+cell+sequestration,+dysfunction+and+deletion.">Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion.</a> Nat Med. 19 (4), 465-472 (2013).</li><li>Overwijk, W. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tumor+regression+and+autoimmunity+after+reversal+of+a+functionally+tolerant+state+of+self-reactive+CD8++T+cells.">Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.</a> J Exp Med. 198 (4), 569-580 (2003).</li><li>Cho, H. I., Celis, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Optimized+peptide+vaccines+eliciting+extensive+CD8+T-cell+responses+with+therapeutic+antitumor+effects.">Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects.</a> Cancer Res. 69 (23), 9012-9019 (2009).</li><li>Ya, Z., Hailemichael, Y., Overwijk, W., Restifo, N. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mouse+model+for+pre-clinical+study+of+human+cancer+immunotherapy.">Mouse model for pre-clinical study of human cancer immunotherapy.</a> Curr Protoc Immunol. 108, 21-43 (2015).</li><li>Menon, V., Thomas, R., Ghale, A. R., Reinhard, C., Pruszak, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Flow+cytometry+protocols+for+surface+and+intracellular+antigen+analyses+of+neural+cell+types.">Flow cytometry protocols for surface and intracellular antigen analyses of neural cell types.</a> J Vis Exp. (94), (2014).</li><li>Durward, M., Harms, J., Splitter, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Antigen+specific+killing+assay+using+CFSE+labeled+target+cells.">Antigen specific killing assay using CFSE labeled target cells.</a> J Vis Exp. (45), (2010).</li></ol>

While this protocol is straightforward, there are a few critical steps that must be carefully performed. The covax priming following injection of the antigen-specific T-cell being tested is necessary to see any killing of the pulsed targets. While it is possible that the water-based covax vaccination creates an acute inflammatory condition, for the chronic inflammatory phase, replacing the short-lived water-based formulation with a slow-antigen release oil-based approach may produce a better outcome7</s...

Multiple protocols exist to assess the cytolytic (CTL) potential of a CD8+ or CD4+ T-cell. This assessment can be readily done in vitro under controlled conditions1,2,3. In addition, infectious disease models, such as LCMV, have classically examined CTL function through the use of differentially CFSE (5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester) labeled target cells where the CFSEhi-labeled cells are pulsed with a peptide and CFSElo-labeled target cells are left unpulsed. The cells are then injected at a 1:1 ratio and assessed for loss of the CFSEhi-labeled pulsed targets by flow cytometry4. Vaccine and rejection models have also used similar strategies for assessment of in vivo killing by both CD8+ and CD4+ T cells as well as NK cells5,6. This is a powerful assay, but requires the use of infectious agents that prime the immune system prior to target injection.
This protocol, on the other hand, requires no prior infection of the host and instead utilizes a vaccination strategy to prime the immune system prior to target injection. This vaccination is comprised of a water-based formulation of peptide vaccine which requires provision of an immunostimulatory cocktail called covax7, consisting of a Toll-like receptor 7 (TLR7) agonist (imiquimod cream), an agonistic anti-CD40 antibody, and interleukin-2 (IL-2) leading to synergistic combination of immunostimulatory agents for the elicitation of peptide-specific priming and robust immune response. As such, this assay provides a quick readout of CTL function as the vaccine is administered along with the cells for assessment of function only three days prior to injection of the target cells. In addition, the covax priming is strong enough that the killing capacity of the primed antigen-specific T cell can be seen between 4 and 24 h after injection.
The major limitation of this protocol is identifying the timeline in vivo for the detection of target killing that is appropriate to both the antigen and the hypothesis being tested. Careful assessment must be performed, as variations in antigen strength as well as genetic alterations being tested in T-cells could result in differential CTL function that would require a different timing detection of target killing. In addition, while the appropriate concentration of peptide for vaccination has been optimized for human melanoma antigen glycopeptide 100 (hgp10025-33) and ovalbumin257-264 (OVA257-264)8,9, use of another antigen model that may be more appropriate to a given study would require further validation. Because of anticipated differences in a target antigens&#39; capacity to stimulate CTL effector function in combination with the covax as an adjuvant, optimization of IL-2 dose concentration and dose frequency may be essential to achieve the desired goal. Overall, this protocol allows for a quick assessment of killing function in vivo and can be adapted to any given antigen.

<table style="border-collapse:collapse;width:523pt" width="697">
	<colgroup>
		<col style="width:199pt" width="265" />
		<col style="width:110pt" width="146" />
		<col style="width:89pt" width="119" />
		<col style="width:125pt" width="167" />
	</colgroup>
	<tbody>
		<tr height="20" style="height:15.0pt">
			<td height="20" style="width:199pt;height:15.0pt" width="265">6- to 12-week old female C57BL/6 mice&#160;</td>
			<td class="xl69" style="width:110pt" width="146">Charles River</td>
			<td class="xl70" style="width:89pt" width="119">027</td>
			<td style="width:125pt" width="167">C57 Black 6 mice</td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">OT-1 6-12-week old female mice&#160;</td>
			<td class="xl70" style="width:110pt" width="146">Jackson Labs</td>
			<td class="xl70" style="width:89pt" width="119">003831</td>
			<td></td>
		</tr>
		<tr height="24" style="height:18.0pt">
			<td height="24" style="height:18.0pt">hgp10025&#8211;33&#160;</td>
			<td class="xl69">CPCScientific</td>
			<td class="xl70" style="width:89pt" width="119">834139</td>
			<td>KVPRNQDWL</td>
		</tr>
		<tr height="24" style="height:18.0pt">
			<td height="24" style="height:18.0pt">OVA 257&#8211;264&#160;</td>
			<td class="xl69">CPCScientific</td>
			<td class="xl70" style="width:89pt" width="119">MISC-012</td>
			<td>SIINFEKL</td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td height="20" style="height:15.0pt">Imiquimod cream 5%&#160;</td>
			<td class="xl69">Fougera</td>
			<td class="xl73">51672-4145-6</td>
			<td>Aldara Cream</td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td height="20" style="height:15.0pt">CD40-specific mAb&#160;</td>
			<td class="xl69">BioXcell</td>
			<td class="xl70" style="width:89pt" width="119">BE0016-2</td>
			<td>clone FGK4.5</td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td height="20" style="height:15.0pt">rhIL-2 protein&#160;</td>
			<td class="xl69">Hoffman LaRoche Inc</td>
			<td class="xl70" style="width:89pt" width="119">136</td>
			<td>Recombinant human IL-2 protein</td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td height="20" style="height:15.0pt">70% isopropyl alcohol Prep&#160;</td>
			<td class="xl69">Kendall</td>
			<td class="xl70" style="width:89pt" width="119">S-17474</td>
			<td></td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td height="20" style="height:15.0pt">PBS</td>
			<td class="xl69">Life Technologies</td>
			<td class="xl70" style="width:89pt" width="119">10010-023</td>
			<td>Phosphate Buffered Saline</td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">FBS</td>
			<td class="xl70" style="width:110pt" width="146">Life Technologies</td>
			<td class="xl70" style="width:89pt" width="119">26140-079</td>
			<td>fetal bovine serum</td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">RBC lysis buffer&#160;</td>
			<td class="xl70" style="width:110pt" width="146">Life Technologies</td>
			<td class="xl70" style="width:89pt" width="119">A10492-01</td>
			<td>red blood cell lysis buffer</td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">RPMI 1640 Media</td>
			<td class="xl70" style="width:110pt" width="146">Life Technologies</td>
			<td class="xl70" style="width:89pt" width="119">11875119</td>
			<td></td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">L-Glutamine&#160;</td>
			<td class="xl70" style="width:110pt" width="146">Life Technologies</td>
			<td class="xl70" style="width:89pt" width="119">25030081</td>
			<td></td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">Pen/Strep</td>
			<td class="xl70" style="width:110pt" width="146">Life Technologies</td>
			<td class="xl70" style="width:89pt" width="119">15140122</td>
			<td>penicillin/streptomycin</td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">CFSE</td>
			<td class="xl70" style="width:110pt" width="146">Life Technologies</td>
			<td class="xl70" style="width:89pt" width="119">C34554</td>
			<td>5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester</td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">Bovine serum albumin (BSA)</td>
			<td class="xl70" style="width:110pt" width="146">Sigma&#160;</td>
			<td class="xl70" style="width:89pt" width="119">A4503</td>
			<td></td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">1.5 mL MCT graduated natural&#160;</td>
			<td class="xl70" style="width:110pt" width="146">Fisher</td>
			<td class="xl70" style="width:89pt" width="119">05-408-129</td>
			<td>microcentrifuge tube</td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">70% ethanol</td>
			<td class="xl70" style="width:110pt" width="146">Fisher</td>
			<td class="xl73">BP8201500</td>
			<td>EtOH</td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">Trypan blue solution, 0.4%&#160;&#160;</td>
			<td class="xl70" style="width:110pt" width="146">Life Technologies</td>
			<td class="xl70" style="width:89pt" width="119">15250-061</td>
			<td></td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">Hemocytometer</td>
			<td class="xl70" style="width:110pt" width="146">Fisher</td>
			<td class="xl70" style="width:89pt" width="119">267110</td>
			<td></td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">27 gauge needle</td>
			<td class="xl70" style="width:110pt" width="146">BD</td>
			<td class="xl70" style="width:89pt" width="119">305109</td>
			<td></td>
		</tr>
		<tr height="20" style="height:15.0pt">
			<td class="xl71" height="20" style="width:199pt;height:15.0pt" width="265">1 mL syringe</td>
			<td class="xl70" style="width:110pt" width="146">BD</td>
			<td class="xl70" style="width:89pt" width="119">309659</td>
			<td></td>
		</tr>
	</tbody>
</table>

in vivo assay for detection of antigen-specific t-cell cytolytic function using a vaccination model

Current methodologies for antigen-specific killing are limited to in vitro use or utilized in infectious disease models. However, there is not a protocol specifically intended to measure antigen-specific killing without an infection. This protocol is designed and describes methods to overcome these limitations by allowing for the detection of antigen-specific killing of a target cell by CD8+ T cells in vivo. This is accomplished by merging a vaccination model with a traditional CFSE-labeled target killing assay. This combination allows the researcher to assess the antigen-specific CTL potential directly and quickly as the assay is not dependent upon tumor growth or infection. In addition, the readout is based on flow cytometry and so should be readily accessible to most researchers. The major limitation of the study is identifying the timeline in vivo that is appropriate to the hypothesis being tested. Variations in antigen strength and mutations in the T cells that may result in differential cytolytic function need to be carefully assessed to determine the optimal time for cell harvest and assessment. The appropriate concentration of peptide for vaccination has been optimized for hgp10025-33 and OVA257-264, but further validation would be needed for other peptides that may be more appropriate to a given study. Overall, this protocol allows a quick assessment of killing function in vivo and can be adapted to any given antigen.

Prior to injection of CFSE-labeled target cells, the 1:1 cell mixture is run on a flow cytometer to determine the baseline frequencies of both the CFSEhi and CFSElo target cells. Figure 1A shows the gating strategy to detect changes in the CFSE populations, an initial gate is made using FSC and SSC parameters. The total CFSE-positive cells are then subgated prior to assessing changes in frequency, as this population is r...

Watch this Scientific Journal Video about In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model at JoVE.com

In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model

The goal of this protocol is to allow for detection of in vivo antigen-specific killing of a target cell in a murine model.

In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model

Current methodologies for antigen-specific killing are limited to in vitro use or utilized in infectious disease models. However, there is not a protocol ...

Research

JoVE Journal

Immunology and Infection

Antigen Specific In Vivo Killing Assay using CFSE Labeled Target Cells

Antigen Specific In Vivo Killing Assay using CFSE Labeled Target Cells

Carboxyfluorescein diacetate succinimidyl ester (CFSE) can be used to easily and quickly label a cell population of interest for in vivo investigation.  ...

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Graft-versus-host disease (GVHD) is the limiting barrier to the broad use of bone marrow transplant as a curative therapy for a variety of hematological ...

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Delayed-type hypersensitivity response (DTH) is a rapid in vivo manifestation of T cell-dependent immune response to a foreign antigen (Ag) that the host ...

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function

T cell exhaustion is a major factor in failed pathogen clearance during chronic viral infections. Immunoregulatory pathways, such as PD-1 and IL-10, are ...

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices

Death of oligodendrocytes accompanied by destruction of neurons and axons are typical histopathological findings in cortical and subcortical grey matter ...

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Traditional vaccine adjuvants, such as alum, elicit suboptimal CD8+ T cell responses. To address this major challenge in vaccine development, various ...

Assessing Retinal Microglial Phagocytic Function In Vivo Using a Flow Cytometry-based Assay

Assessing Retinal Microglial Phagocytic Function In Vivo Using a Flow Cytometry-based Assay

Microglia are the tissue resident macrophages of the central nervous system (CNS) and they perform a variety of functions that support CNS homeostasis, ...

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain

T cell receptors (TCRs) are used clinically to direct the specificity of T cells to target tumors as a promising modality of immunotherapy. Therefore, ...

Detection and Enrichment of Rare Antigen-specific B Cells for Analysis of Phenotype and Function

B cells reactive with a specific antigen usually occur at a frequency of &lt;0.05% of lymphocytes. For decades researchers have sought methods to isolate ...

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

We provide a detailed overview of a novel high-throughput protein microarray assay for the determination of anti-Clostridium difficile antibody levels in ...